Creative Planning increased its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 17.0% in the 4th quarter, HoldingsChannel reports. The fund owned 66,572 shares of the medical research company’s stock after purchasing an additional 9,665 shares during the period. Creative Planning’s holdings in EXACT Sciences were worth $4,201,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in EXAS. CWM LLC increased its position in EXACT Sciences by 777.1% in the 4th quarter. CWM LLC now owns 614 shares of the medical research company’s stock worth $39,000 after purchasing an additional 544 shares during the last quarter. Strs Ohio acquired a new position in EXACT Sciences in the 4th quarter worth about $161,000. Meeder Asset Management Inc. increased its position in EXACT Sciences by 602.9% in the 4th quarter. Meeder Asset Management Inc. now owns 2,910 shares of the medical research company’s stock worth $184,000 after purchasing an additional 2,496 shares during the last quarter. Chicago Partners Investment Group LLC increased its position in EXACT Sciences by 47.6% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock worth $191,000 after purchasing an additional 1,000 shares during the last quarter. Finally, First Republic Investment Management Inc. acquired a new position in EXACT Sciences in the 3rd quarter worth about $204,000. 91.80% of the stock is owned by hedge funds and other institutional investors.
EXAS has been the topic of several research reports. Canaccord Genuity upped their target price on EXACT Sciences from $87.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, January 14th. Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a research report on Friday, January 25th. UBS Group began coverage on EXACT Sciences in a report on Tuesday, October 9th. They set a “buy” rating and a $100.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of EXACT Sciences in a report on Monday, January 7th. Finally, Jefferies Financial Group increased their price objective on EXACT Sciences from $74.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. EXACT Sciences presently has an average rating of “Buy” and a consensus target price of $90.45.
Shares of NASDAQ EXAS opened at $87.10 on Wednesday. The company has a current ratio of 12.08, a quick ratio of 11.72 and a debt-to-equity ratio of 0.94. The stock has a market cap of $10.70 billion, a PE ratio of -87.98 and a beta of 1.83. EXACT Sciences Co. has a 52 week low of $37.36 and a 52 week high of $90.80.
In other EXACT Sciences news, insider Kevin T. Conroy sold 304,397 shares of the firm’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $81.27, for a total value of $24,738,344.19. Following the sale, the insider now owns 1,190,408 shares of the company’s stock, valued at approximately $96,744,458.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jeffrey Thomas Elliott sold 90,909 shares of the firm’s stock in a transaction that occurred on Thursday, January 24th. The shares were sold at an average price of $78.90, for a total value of $7,172,720.10. Following the completion of the sale, the chief financial officer now directly owns 124,120 shares in the company, valued at approximately $9,793,068. The disclosure for this sale can be found here. In the last three months, insiders have sold 568,068 shares of company stock worth $43,821,761. 3.20% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://theenterpriseleader.com/2019/02/06/exact-sciences-co-exas-shares-bought-by-creative-planning.html.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Read More: Different Types of Derivatives
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.